Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]United Therapeutics"
Count: 122
Selected: 0
NCT IDTitle
NCT03683186A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03626688A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
NCT04084678A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH
NCT03794583Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
NCT03496623A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
NCT03497689EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
NCT03045029ADAPT - A Patient Registry of the Real-world Use of Orenitram®
NCT04708782Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT02630316Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
NCT02279745Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
NCT01560637An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
NCT03857841A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD
NCT04905693Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT01027949An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
NCT03950739Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
NCT02633293An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
NCT02261883Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
NCT03888365Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
NCT03098030Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
NCT03037580Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
NCT03043651Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF
NCT02279160Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
NCT01560624Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
NCT02693171Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
NCT02276872Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
NCT02893995Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
NCT02882126An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension
NCT02999906Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
NCT02847260Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
NCT00325442FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT03055221TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
NCT03055234Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)
NCT03016468Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
NCT03012646Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD
NCT01477333Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
NCT01028651A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
NCT01934582A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
NCT01104870A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
NCT01588405Remodulin® to Oral Treprostinil Transition
NCT01795950Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)
NCT01266265Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
NCT02603068Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
NCT01592045ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
NCT02318758Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers
NCT01799473Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
NCT02149095Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers
NCT00775463Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine
NCT00848107Open-Label Study of Oral Treprostinil in Digital Ulcers
NCT00494533Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension
NCT00147199Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)